![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, December 08, 2020 12:24:12 PM
Their inability to meet any timeline is keeping the SP down
It's not an "inability". It is 100 percent willful. They have been playing games with shareholders for many years, and what they are doing now is continuing their efforts to secretly manipulate the data to meet a desired outcome.
The way I see it, there are two equally likely possibilities from here:
Scenario 1) They release the data on Monday, Dec. 14, ahead of the options deadline. It will be a puffed up press release that talks about the great contribution this trial will make to the field of cancer vaccine research. Of course, what it will be referring to is future cancer vaccine research, because the data will show a failed trial due to invalid comparisons. Knowing these people as I do, I predict they will try to present a failed trial as actually being a successful trial, because the invalid comparisons may reflect minimal efficacy in one or two endpoints. They will tout this as actual success, and decry the injustice of having their grossly manipulated trial ruled invalid.
Stock price will plummet.
Scenario 2) They announce the warrants have been extended again - until March or April at least - and at the same time announce another cash raise that further dilutes common shareholders so they can keep paying themselves. Wash, rinse, repeat. In this scenario we carry on as we always have, and begin talking about making a really, really tough list of questions for the ASM, and then begin hyping the super expensive and professional looking background the company has created for its 2021 ASCO Zoom presentation. Everything proceeds per usual until we eventually get back around to Scenario 1.
Stock price drops under a dollar, and begins a slow decline back to $.17
It will be one of these two scenarios. Count on it.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM